Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2005-02-03
2010-12-21
Skowronek, Karlheinz R (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C600S368000
Reexamination Certificate
active
07856319
ABSTRACT:
The present invention is drawn to a new diagnosis method for detecting the extent of alcoholic or non-alcoholic steato-hepatitis in a patient, in particular in a patient suffering from a disease involving alcoholic or non-alcoholic steato-hepatitis or who already had a positive diagnosis test of liver fibrosis and/or presence of liver necroinflammatory lesions, by using the serum concentration of easily detectable biological markers. The invention is also drawn to diagnosis kits for the implementation of the method.
REFERENCES:
patent: 6631330 (2003-10-01), Poynard
patent: 7225080 (2007-05-01), Poynard
patent: 2004/0039553 (2004-02-01), Poynard
Wanless IR Lentz JS (Abstract) Hepatology 1990 12 1106-10.
Sanyal (Gastroenterology,vol. 123, p. 1705-1725, 2002).
Nyblom et al. (Alcohol & Alcoholism vol. 39, No. 4, pp. 336-339, 2004).
Arteel et al. (Best Practice & Research Clinical Gastroenterology vol. 17, No. 4, pp. 625-647, 2003).
Papadia et al. (Obesity Surgery, vol. 14, p. 952-958, 2004).
Sorbi et al. (American Journal of Gastroenterology, vol. 94, No. 4, p. 1018-1022, 1999).
Angulo, “Nonalcoholic Fatty Liver Disease,”N Engl J Med, vol. 346, No. 16, 1221-1231 (Apr. 18, 2002).
Annoni et al., “Serum Type III Procollagen Peptide and Laminin (Lam-P1) Detect Alcoholic Hepatitis in Chronic Alcohol Abusers,”Hepatology, vol. 9, No. 5, pp. 693-697 (1989).
Bedossa et al., “Observer Variation in Assessment of Liver Biopsies of Alcoholic Patients,”Alcohol Clin Exp Res, 12(1):173-178 (1988).
Callewaert et al., “Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics,”Nat Med, 10(4):429-434 (Apr. 2004).
Castera et al., “Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis,”J Hepatol, 32(3):412-418 (2000).
Chossegros, “Extracellular martix serum markers (ECMSM) in alcoholic liver disease,”J Hepatol, 22(Suppl. 2):96-99 (1995).
Halfon et al., “A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease,”Comp Hepatology, 1:3 (2002).
Imbert-Bismut et al., “Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors,”Clin Chem Lab Med, 42(3):323-333 (2004).
Levitsky et al., “Diagnosis and Therapy of Alcoholic Liver Disease,”Seminars in Liver Dis, 24(3):233-247 (2004).
Maher, “Alcoholic Steatosis and Steatohepatitis,”Seminars in Gastrointest Dis, 13(1):31-39 (2002).
Mathurin et al., “Survival and Prognostic Factors in Patients With Severe Alcoholic Hepatitis Treated With Prednisolone,”Gastroenterology, 110(6):1847-1853 (1996).
Mathurin et al., “Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH,”Journal of Hepatology, 36(4):480-487 (2002).
Munteanu et al., Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest),Comp Hepatology, 3:3 (2004).
Myers et al., “Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B,”Journal of Hepatology, 39(2):222-230 (2003).
Naveau et al., “Biomarkers for the Prediction of Liver Fibrosis in Patients With Chronic Alcoholic Liver Disease,”Clin Gastroenterol and Hepatol, 3(2):167-174 (2005).
Nøjgaard et al., “Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease,”Journal of Hepatology, 39(2):179-186 (2003).
Poynard et al., “Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C,”Comp Hepatol, 3(1):8 (2004).
Poynard et al., “Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival,”Journal of Hepatology, 30:1130-1137 (1999).
Poynard et al., “Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C,”Clin Chem, 50(8):1344-1355 (2004).
U.S. Appl. No. 11/050,396, filed Feb. 3, 2005, Poynard, Non-Final Rejection, Aug. 8, 2007.
U.S. Appl. No. 11/050,396, filed Feb. 3, 2005, Poynard, Amendment and Response to Office Action, Nov. 13, 2007.
U.S. Appl. No. 11/050,396, filed Feb. 3, 2005, Poynard, Non-Final Rejection, Feb. 8, 2008.
U.S. Appl. No. 11/050,396, filed Feb. 3, 2005, Poynard, Amendment and Response to Office Action, May 9, 2008.
U.S. Appl. No. 11/050,396, filed Feb. 3, 2005, Poynard, Non-Final Rejection, Sep. 9, 2008.
U.S. Appl. No. 11/050,396, filed Feb. 3, 2005, Poynard, Amendment and Response to Office Action, Feb. 6, 2009.
U.S. Appl. No. 11/050,396, filed Feb. 3, 2005, Poynard, Examiner's Interview Summary Record, Feb. 20, 2009.
U.S. Appl. No. 11/815,332, filed Feb. 3, 2006, Poynard, Preliminary Amendment, Feb. 5, 2009.
Ratziu et al., “Screening for Liver Disease using Non-Invasive Biomarkers (FibroTest, SteatoTest and NashTest) in Patients with Hyperlipidaemia,”Alimentary Pharmacology&Therapeutics, (25): 207-218 (2007).
Thabut et al., “The Diagnostic Value of Biomarkers (AshTest) for the Prediction of Alcoholic Steato-Hepatitis in Patients with Chronic Alcoholic Liver Disease,”Journal of Hepatology, (44): 1175-1185 (2006).
Bedossa et al., “An Algorithm for the Grading of Activity in Chronic Hepatitis C,”Journal of Hepatology, 24(2): 289-293 (1996).
Zweig et al., “Receiver-Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine,”Clinical Chemistry, 39(4): 561-577 (1993).
Assistance Publique-Hopitaux de Paris (Ap-Hp)
Ballard Spahr LLP
Skowronek Karlheinz R
LandOfFree
Diagnosis method of alcoholic steato-hepatitis using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis method of alcoholic steato-hepatitis using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis method of alcoholic steato-hepatitis using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171952